Etiological diagnosis of neurocognitive disorders of middle-old age relies on biomarkers,
although evidence for their rational use is incomplete. A European task force is defining
a diagnostic workflow where expert experience fills evidence gaps for biomarker validity
and prioritization. We report methodology and preliminary results.Using a Delphi consensus
method supported by a systematic literature review, 22 delegates from 11 relevant
scientific societies defined workflow assumptions.We extracted diagnostic accuracy
figures from literature on the use of biomarkers in the diagnosis of main forms of
neurocognitive disorders. Supported by this evidence, panelists defined clinical setting
(specialist outpatient service), application stage (MCI-mild dementia), and detailed
pre-assessment screening (clinical-neuropsychological evaluations, brain imaging,
and blood tests).The Delphi consensus on these assumptions set the stage for the development
of the first pan-European workflow for biomarkers' use in the etiological diagnosis
of middle-old age neurocognitive disorders at MCI-mild dementia stages.Rational use
of biomarkers in neurocognitive disorders lacks consensus in Europe. A consensus of
experts will define a workflow for the rational use of biomarkers. The diagnostic
workflow will be patient-centered and based on clinical presentation. The workflow
will be updated as new evidence accrues.
